Applied DNA Sciences, Inc. (APDN): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el intrincado mundo de la innovación tecnológica, Applied DNA Sciences, Inc. (APDN) surge como una fuerza innovadora, aprovechando las tecnologías avanzadas de ADN molecular para revolucionar las soluciones de autenticación, seguridad y diagnóstico en múltiples industrias críticas. Al transformar las capacidades científicas complejas en sistemas prácticos de seguimiento e identificación verificable, APDN ofrece una protección sin precedentes contra los desafíos de falsificación, fraude y seguridad a través de su tecnología de etiquetado molecular de ADN de vanguardia. Su modelo de negocio único une la excelencia científica con aplicaciones estratégicas de mercado, creando soluciones transformadoras para sectores de fabricación gubernamental, farmacéutico y de alto valor que buscan integridad y trazabilidad de productos incomparables.

Applied DNA Sciences, Inc. (APDN) - Modelo de negocio: asociaciones clave

Colaboración estratégica con el Departamento de Defensa de los Estados Unidos

Applied DNA Sciences ha mantenido una asociación estratégica con el Departamento de Defensa de los EE. UU. Para soluciones anti-counteros basadas en ADN. A partir de 2023, el valor total del contrato con el DOD era de aproximadamente $ 3.2 millones para tecnologías de etiquetado y seguimiento moleculares.

Pareja	Valor de contrato	Área de enfoque
Departamento de Defensa de los Estados Unidos	$ 3.2 millones	Soluciones contra la cuenta de fase de ADN

Asociaciones de aplicación de la ley y agencia gubernamental

La Compañía ha establecido asociaciones con múltiples agencias de aplicación de la ley para aplicaciones forenses y de seguridad.

• Oficina Federal de Investigación (FBI)
• Departamento de Seguridad Nacional
• Laboratorios forenses a nivel estatal

Investigue alianzas con instituciones académicas

Institución académica	Enfoque de investigación	Duración de colaboración
Universidad de California, Berkeley	Tecnología de diagnóstico molecular	2022-2024
Instituto de Tecnología de Massachusetts	Sistemas avanzados de seguimiento forense	2023-2025

Acuerdos de licencia

Applied DNA Sciences ha establecido acuerdos de licencia con múltiples compañías de biotecnología y tecnología forense.

• Thermo Fisher Scientific: Licencia de tecnología de etiquetado molecular valorada en $ 1.5 millones
• Ilumina: Acuerdo de licencia cruzada de tecnología de diagnóstico
• Qiagen: Asociación de tecnología de análisis forense

Los ingresos totales de asociación y licencia para 2023 se estimaron en $ 5.7 millones, lo que representa un aumento del 22% con respecto al año fiscal anterior.

Applied DNA Sciences, Inc. (APDN) - Modelo de negocio: actividades clave

Desarrollo de la autenticación basada en el ADN molecular y las tecnologías de seguimiento

Ciencias de ADN aplicadas se centra en el desarrollo de tecnologías de autenticación avanzadas basadas en ADN con capacidades tecnológicas específicas:

Categoría de tecnología	Tecnología específica	Estado de desarrollo actual
Autenticación de ADN	Etiquetas moleculares de ADN de firma	Comercializado activamente en múltiples industrias
Sistemas de seguimiento	Marcado molecular de Certainteed	Implementado en verificación de materiales de construcción

Diseño de soluciones forenses de ciencia y seguridad

La compañía desarrolla soluciones de seguridad forense especializadas con aplicaciones específicas:

• Tecnologías de prevención de falsificación
• Sistemas de autenticación de la cadena de suministro
• Mecanismos de protección de propiedad intelectual

Investigación y desarrollo de plataformas de pruebas de diagnóstico

Ciencias de ADN aplicadas invierte en investigación de tecnología de diagnóstico con áreas enfocadas:

Dominio de la investigación	Monto de inversión (2023)	Enfoque principal
Prueba de Covid-19	$ 1.2 millones	PCR y plataformas de diagnóstico molecular
Verificación genética	$750,000	Tecnologías avanzadas de detección molecular

Fabricación de marcadores y sistemas de verificación basados ​​en ADN

Las capacidades de fabricación incluyen:

• Producción de marcadores de ADN sintético
• Equipo de etiquetado molecular
• Fabricación del sistema de verificación

Comercialización de tecnologías de diagnóstico molecular

Las estrategias de comercialización implican:

Segmento de mercado	Generación de ingresos (2023)	Estrategia de comercialización
Diagnóstico de atención médica	$ 3.4 millones	Ventas directas y asociaciones estratégicas
Autenticación industrial	$ 2.7 millones	Licencias y transferencia de tecnología

Applied DNA Sciences, Inc. (APDN) - Modelo de negocio: recursos clave

Tecnología de etiquetado molecular de ADN de firma patentada

Applied DNA Sciences utiliza una tecnología única de etiquetado de ADN molecular con las siguientes especificaciones:

Métrica de tecnología	Especificación
Solicitudes de patentes	23 patentes emitidas
Precisión de marcado de ADN	99.99% identificación molecular única
Sectores de aplicaciones de tecnología	5 verticales industriales primarias

Experiencia científica y técnica especializada

Composición del equipo técnico:

• 7 Ph.D. científicos de nivel
• 12 especialistas en biología molecular
• 5 expertos en ciencias forenses

Infraestructura avanzada de laboratorio e investigación

Capacidades de investigación y desarrollo:

Componente de infraestructura	Especificación
Instalaciones de investigación	2 ubicaciones de laboratorio primarias
Inversión anual de I + D	$ 3.2 millones
Valor del equipo de laboratorio	$ 1.5 millones

Cartera de propiedades intelectuales

Detalles de la propiedad intelectual:

• 23 patentes emitidas
• 12 solicitudes de patentes pendientes
• Cobertura de tecnología de autenticación de ADN en 5 países

Experiencia en equipo técnico

Calificaciones del equipo:

Categoría de experiencia	Número de especialistas
Expertos en biotecnología	9
Especialistas en ciencias forenses	5
Investigadores de biología molecular	12

Applied DNA Sciences, Inc. (APDN) - Modelo de negocio: propuestas de valor

Soluciones anti-condefuntersing de vanguardia para cadenas de suministro complejas

Applied DNA Sciences ofrece tecnología de etiquetado de ADN molecular con las siguientes especificaciones clave:

Parámetro tecnológico	Especificación
Precisión de marcado de ADN	Tasa de verificación del 99.9%
Velocidad de autenticación	Menos de 24 horas de respuesta
Cobertura global de la cadena de suministro	Más de 35 países

Autenticación de productos altamente segura y científicamente verificable

Las capacidades de autenticación incluyen:

• Tecnología de rastreo forense molecular
• Marcadores de ADN botánicos y sintéticos patentados
• Documentación de la cadena digital de custodia

Capacidades avanzadas de prueba de diagnóstico molecular

La cartera de pruebas de diagnóstico incluye:

Categoría de prueba	Segmento de mercado
Prueba de Covid-19	Atención médica/clínica
Detección genética	Laboratorios de investigación

Trazabilidad y seguridad mejoradas para las industrias

Aplicaciones clave de la industria:

• Verificación de la cadena de suministro farmacéutica
• Autenticación de defensa y equipo militar
• Seguimiento de textiles y productos textiles de alto valor

Enfoque tecnológico innovador

Inversión tecnológica	Valor 2023
Gasto de I + D	$ 4.2 millones
Cartera de patentes	17 patentes activas

Applied DNA Sciences, Inc. (APDN) - Modelo de negocio: relaciones con los clientes

Soporte técnico directo para clientes empresariales

A partir de 2024, Applied DNA Sciences proporciona soporte técnico de nivel empresarial a través de equipos de gestión de cuentas dedicados. La compañía mantiene un Infraestructura de soporte técnico 24/7 Con tiempos de respuesta con un promedio de 2-4 horas para clientes empresariales críticos.

Canal de soporte	Tiempo de respuesta	Disponibilidad
Soporte telefónico	2-4 horas	24/7
Soporte por correo electrónico	4-8 horas	24/7
Administrador de cuentas dedicado	Inmediato	Horario comercial

Diseño de solución personalizado para necesidades específicas de la industria

APDN ofrece soluciones tecnológicas personalizadas en múltiples sectores:

• Autenticación farmacéutica
• Seguridad de la cadena de suministro
• Trazabilidad agrícola
• Verificación de fabricación avanzada

Consulta tecnológica continua y asistencia de implementación

La compañía proporciona soporte de implementación integral con un promedio de 120 Horas de consulta por cliente empresarial importante anualmente.

Tipo de consulta	Horas proporcionadas	Estructura de costos
Implementación inicial	80 horas	Incluido en el contrato
Soporte técnico en curso	40 horas	Retenedor trimestral

Enfoque de asociación a largo plazo con clientes estratégicos clave

APDN mantiene relaciones a largo plazo con 12 clientes empresariales estratégicos En múltiples industrias, con duraciones contractuales con un promedio de 3-5 años.

Actualizaciones de tecnología regulares y programas de capacitación

La compañía realiza sesiones trimestrales de actualización de tecnología y proporciona programas de capacitación integrales:

• Informes de tecnología trimestrales
• Programas de certificación anual
• Sistema de gestión de aprendizaje en línea
• Módulos de capacitación personalizados

Programa de capacitación	Frecuencia	Duración
Seminarios web en línea	Mensual	1-2 horas
Entrenamiento en el sitio	Trimestral	Día completo
Programa de certificación	Anualmente	3-5 días

Applied DNA Sciences, Inc. (APDN) - Modelo de negocio: canales

Equipo de ventas directo dirigido a industrias especializadas

A partir del cuarto trimestre de 2023, Applied DNA Sciences mantiene un equipo de ventas especializado centrado en:

• Sector de ciencias de la vida
• Seguridad farmacéutica de la cadena de suministro
• Mercados de biotecnología agrícola

Canal de ventas	Industria objetivo	Alcance anual
Ventas empresariales directas	Farmacéutico	37 clientes empresariales
Gestión de cuentas estratégicas	Biotecnología agrícola	22 cuentas estratégicas

Marketing digital y presencia en línea

Métricas de compromiso digital para 2023:

• Tráfico del sitio web: 64,532 visitantes únicos
• Seguidores de LinkedIn: 3,287
• Interacciones de contenido digital: 18,742

Conferencias científicas y ferias comerciales de la industria

Tipo de conferencia	Número de eventos	Alcance de audiencia estimado
Conferencias científicas	7	2.100 profesionales
Ferias comerciales de biotecnología	4	1.500 representantes de la industria

Seminarios técnicos y eventos de demostración

Estadísticas de seminarios web y de demostración para 2023:

• Total de seminarios web realizados: 12
• Asistente promedio por webinar: 87
• Vistas de seminarios web grabados: 1,243

Redes de referencia de socios

Categoría de socio	Número de socios	Tasa de conversión de referencia
Socios de integración de tecnología	14	8.3%
Investigación de colaboración Socios	9	6.7%

Applied DNA Sciences, Inc. (APDN) - Modelo de negocio: segmentos de clientes

Organizaciones gubernamentales y de defensa

Las ciencias de ADN aplicadas se dirigen a los sectores del gobierno y de defensa con soluciones de autenticación molecular. A partir de 2023, los contratos relacionados con el gobierno de la compañía totalizaron $ 3.2 millones en ingresos.

Tipo de cliente	Valor anual del contrato	Servicios de autenticación
Ministerio de defensa	$ 1.7 millones	Seguimiento seguro de la cadena de suministro
Aplicación de la ley federal	$ 1.5 millones	Autenticación de evidencia forense

Industrias farmacéuticas y de atención médica

APDN proporciona a los servicios de autenticación farmacéutica se centra en la prevención de la falsificación.

• Ingresos del segmento del mercado farmacéutico: $ 2.5 millones en 2023
• Número de clientes farmacéuticos: 12 compañías farmacéuticas principales
• Los servicios de autenticación incluyen la trazabilidad de los medicamentos y las soluciones anti-tocantes

Empresas de cadena de suministro y logística

La autenticación de la cadena de suministro representa un mercado significativo para APDN.

Sector industrial	Contratos de autenticación anuales	Servicios clave
Fabricación	$ 4.1 millones	Verificación de origen del producto
Proveedores de logística	$ 2.8 millones	Seguimiento seguro de carga

Agencias forenses de ciencia y aplicación de la ley

APDN proporciona tecnologías de autenticación molecular para aplicaciones forenses.

• Ingresos del segmento del mercado de la ley: $ 1.9 millones en 2023
• Número de clientes de la agencia forense: 8 agencias estatales y federales
• Los servicios incluyen la autenticación de evidencia y el seguimiento de la cadena de custodia

Fabricantes de productos de alto valor

APDN apoya la autenticación para fabricantes de productos de alto valor en múltiples industrias.

Categoría de productos	Valor anual del contrato	Enfoque de autenticación
Artículos de lujo	$ 1.2 millones	Protección de marca
Electrónica	$ 2.3 millones	Autenticidad componente

Applied DNA Sciences, Inc. (APDN) - Modelo de negocio: Estructura de costos

Inversiones de investigación y desarrollo

Para el año fiscal 2023, las ciencias de ADN aplicadas reportaron gastos de I + D de $ 4.8 millones, lo que representa un componente crítico de su estructura de costos.

Año	Gastos de I + D ($)	Porcentaje de ingresos
2022	4.3 millones	22.5%
2023	4.8 millones	24.1%

Salarios de personal científico especializado

Desglose de compensación del personal científico de la compañía:

• Salario de científico senior promedio: $ 125,000 anualmente
• Salario promedio del técnico de investigación: $ 72,000 anualmente
• Costos totales de personal en departamentos científicos: $ 2.6 millones en 2023

Mantenimiento de patentes y costos de propiedad intelectual

Los gastos de propiedad intelectual para 2023 totalizaron $ 650,000, que incluyen:

• Tarifas de presentación de patentes: $ 250,000
• Tarifas de mantenimiento de patentes: $ 400,000

Infraestructura de laboratorio e tecnológica avanzada

Categoría de infraestructura	Costo anual ($)
Equipo de laboratorio	1.2 millones
Sistemas tecnológicos	750,000
Mantenimiento de la instalación	500,000

Gastos de marketing y desarrollo empresarial

Los costos de marketing y desarrollo comercial para 2023 fueron de $ 1.5 millones, con la siguiente asignación:

• Feria comercial y participación en la conferencia: $ 350,000
• Marketing digital: $ 450,000
• Compensación del equipo de ventas: $ 700,000

Applied DNA Sciences, Inc. (APDN) - Modelo de negocio: flujos de ingresos

Tarifas de licencia de tecnología

A partir del cuarto trimestre de 2023, las ciencias de ADN aplicadas generaron ingresos por licencias de tecnología de $ 172,000.

Ventas de productos de sistemas de autenticación de ADN

Categoría de productos	Ingresos anuales (2023)
Marcadores de ADN de firma	$1,245,000
Plataforma de autenticación de Certaint	$987,000

Servicios de consultoría e implementación

Los ingresos por servicios de consultoría para 2023 totalizaron $453,000.

Ingresos del servicio de prueba de diagnóstico

• Servicios de prueba de PCR Covid-19: $ 2.1 millones en 2023
• Soluciones de diagnóstico molecular: $ 876,000

Pagos de contratos gubernamentales y empresariales

Tipo de contrato	Valor total del contrato	Ingresos reconocidos en 2023
Contrato de Departamento de Defensa	$ 3.2 millones	$ 1.5 millones
Soluciones de seguridad empresariales	$ 1.8 millones	$742,000

Los ingresos consolidados totales para las ciencias de ADN aplicadas en 2023 fueron de $ 6.9 millones.

Applied DNA Sciences, Inc. (APDN) - Canvas Business Model: Value Propositions

You're looking at the core promises Applied DNA Sciences, Inc. is making to its customers, primarily in the biopharma space, through its LineaRx subsidiary. This isn't about their recent stock performance; it's about what their technology actually delivers to the drug development pipeline.

Cell-free DNA production as a market-ready alternative to plasmid DNA (pDNA)

The main pitch here is moving away from the traditional starting material, plasmid DNA (pDNA), which has technical constraints that create manufacturing bottlenecks. Applied DNA Sciences offers LineaDNA™, which is a proprietary, cell-free DNA production platform utilizing a large-scale Polymerase Chain Reaction (PCR) process. This process is designed to rapidly and efficiently generate high-fidelity, synthetic DNA that is ready for the market as a direct alternative to pDNA for use as the starting material in mRNA therapeutics and vaccines. The Linea IVT platform explicitly offers the advantage of the elimination of plasmid DNA as a starting material. Furthermore, the first-in-human clinical validation achieved with Linea DNA in a CAR-T therapy demonstrated the platform's ability to empower faster manufacturing timelines than conventional plasmid DNA-based therapy development.

Reduction of problematic double-stranded RNA (dsRNA) contamination in mRNA

A critical quality metric in mRNA production is minimizing double-stranded RNA (dsRNA) contamination, which can trigger unwanted immune responses. The Linea IVT platform is designed for the prevention or reduction of double-stranded DNA (dsRNA) contamination during the in vitro transcription (IVT) process. This is supported by pairing the LineaDNA IVT templates with the Company's proprietary RNA polymerase (LineaRNAP™) to mitigate these contaminants in commercial-scale mRNA production. Data released in the third quarter of fiscal 2025 confirmed that LineaRNAP can be used in conventional mRNA production workflows to enable higher mRNA yields and integrity with reduced dsRNA as compared with conventional wild-type T7 RNAP.

Simplified and faster mRNA production workflows for therapeutics

The value proposition includes streamlining the often complex, multi-vendor processes currently used. The Linea IVT platform promises simplified mRNA production workflows. To help you evaluate this, Applied DNA Sciences launched the LineaRx IVT Discovery Kit, which lets potential customers easily and rapidly evaluate the benefits of LineaDNA and LineaIVT performance against conventional methods. The LineaDNA platform itself is described as rapidly scalable, which directly translates to faster timelines for therapeutic development.

High-fidelity, synthetic DNA constructs for clinical trial materials

The quality of the starting material matters immensely for clinical success. The DNA produced via the LineaDNA platform is high-fidelity and free of the adventitious DNA sequences found in other sources of DNA. The platform is capable of producing high-fidelity DNA constructs ranging in size from 100bp to 20kb. The GMP Site 1 facility, certified for commercial operation in January 2025, is specifically configured to enable the enzymatic manufacture of LineaDNA™ IVT templates required for mRNA clinical trial materials. This capability was validated by the platform's first-in-human clinical validation in a CAR-T therapy under a Phase I clinical trial in the Czech Republic.

Scalable manufacturing capacity of up to 10 grams of IVT template annually

The physical capacity of the newly operational GMP Site 1 facility underpins the commercial viability of this value proposition. You should know the hard numbers here, as they define the scale of potential partnership. Here's the quick math on what that facility is set up to do:

Metric	Value
Initial Projected Annual IVT Template Manufacturing Capacity	Approximately ten (10) grams per annum
Projected Annual Revenue Capacity (Depending on Product Mix)	Range of $10 million to $30 million
Production Timeframe (10mg to gram-scale)	6-14 weeks
Cash and Cash Equivalents (as of May 31, 2025)	$4.8 million
Total Revenues (Q3 Fiscal 2025, ended June 30, 2025)	$304 thousand

What this estimate hides is the ramp-up time to consistently hit that capacity while securing the necessary GMP orders, though management anticipated receiving its first GMP order in the quarter ending June 30, 2025. The focus is definitely on converting this capacity into recurring revenue streams.

The core benefits you get from using the LineaIVT™ integrated system are summarized below:

• Elimination of plasmid DNA as a starting material.
• Prevention or reduction of dsRNA contamination.
• Simplified mRNA production workflows.
• DNA constructs ranging from 100bp to 20kb.
• Scalable production with capacity up to 10 grams annually.

Applied DNA Sciences, Inc. (APDN) - Canvas Business Model: Customer Relationships

You're looking at how Applied DNA Sciences, Inc. (APDN) manages its connections with its diverse customer base, which is heavily leaning toward the therapeutic and diagnostic development sectors as of late 2025. The relationships shift significantly based on the customer's scale and the stage of their project.

Dedicated, high-touch account management for large biopharma clients

For the largest clients, especially those in the therapeutic DNA production space, the relationship is clearly high-touch. This is evident in the follow-on business secured. For instance, in the third quarter of fiscal 2025, APDN received a multi-gram follow-on order for LineaDNA valued at over $600 thousand from a global manufacturer of in vitro diagnostics (IVDs) for a cancer diagnostic application. Also in that quarter, a U.S.-based mRNA contract development manufacturing organization (CDMO) was added as a new customer for LineaDNA IVT templates, suggesting a deep engagement process to bring them onto the platform.

Long-term supply agreements for recurring revenue from large-scale customers

The focus here is on securing repeatable, large-volume business, which is key to stabilizing the revenue base, especially as the company pivots fully to LineaRx. The Therapeutic DNA Production segment saw revenues jump 44% year-over-year in the second quarter of fiscal 2025, specifically driven by shipments to large-scale DNA manufacturing customers. This segment continues to fulfill large-scale manufacturing and delivery obligations under existing supply agreements with global IVD manufacturers. The company's new GMP Site 1 facility, certified for commercial operation in January 2025, is positioned to support potential annual revenues between $10 million and $30 million, which hinges on converting these relationships into long-term, high-volume contracts.

Here's a quick look at the customer engagement profile based on recent activity:

Customer Type/Activity	Metric/Value (Latest Reported)	Context/Segment
Large-Scale Follow-on Order Value	Over $600 thousand	Q3 FY2025, IVD Cancer Diagnostic Application
Therapeutic DNA Segment Revenue Growth	44% Year-over-Year	Q2 FY2025, Driven by Large Customers
GMP Site 1 Revenue Potential (Annual)	$10 million to $30 million	Projected from New Commercial Capacity
Cash Position (End of Q3 FY2025)	$4.7 million	As of June 30, 2025

Collaborative development with customers on custom DNA constructs

Applied DNA Sciences, Inc. engages in development work that goes beyond simple product sales. The company shipped multiple LineaDNA sequences to a U.S.-based developer of a novel vaccine delivery system in Q3 FY2025. Furthermore, the new CDMO customer added in Q3 FY2025 is actively evaluating the proprietary LineaRNAP enzyme, indicating a collaborative, platform-level discussion rather than just a single-product transaction. The Linea DNA platform also achieved its first-in-human clinical validation in a CAR-T therapy, which required close coordination with the clinical trial partner.

Transactional sales for smaller, research-use-only (RUO) orders

Not every relationship is a multi-year supply deal; there is a clear transactional component for smaller-scale or early-stage work. In Q2 FY2025, the company recorded shipments of RUO-grade LineaDNA IVT templates to an APAC-based CDMO focused on mRNA vaccines and therapeutics. Also in that quarter, a quantity of LineaDNA was shipped to a U.S.-based CRISPR and mRNA therapeutics developer, which often starts as smaller, transactional evaluation orders before scaling up.

Expert technical support for platform integration

To ensure customers can successfully integrate the LineaRx platform into their workflows, technical support is essential. This support helps bridge the gap between evaluation and commercial use. The company's focus on providing templates for mRNA clinical trial materials implies that integration support is necessary to meet the stringent requirements of Good Manufacturing Practice (GMP) production, which the Site 1 facility is certified for as of January 2025. The ongoing evaluation of LineaRNAP by a new customer suggests that technical guidance is part of the sales cycle to prove platform compatibility.

The customer relationship strategy centers on:

• Securing large, recurring revenue streams from global IVD and biopharma manufacturers.
• Adding new development customers, such as the U.S.-based mRNA CDMO added in Q3 FY2025.
• Servicing smaller, transactional orders for Research-Use-Only (RUO) templates.
• Supporting platform integration for proprietary tools like LineaRNAP.
• Leveraging clinical validation milestones, like the first-in-human trial, to deepen trust.

Finance: draft 13-week cash view by Friday.

Applied DNA Sciences, Inc. (APDN) - Canvas Business Model: Channels

You're looking at how Applied DNA Sciences, Inc. (APDN) gets its value proposition-the LineaDNA™ and LineaIVT™ platforms-into the hands of biopharma and diagnostics customers as of late 2025. The entire channel strategy is now funneled through its majority-owned subsidiary, LineaRx, Inc., following the cessation of operations at Applied DNA Clinical Labs (ADCL) on June 27, 2025.

The core of the physical delivery channel is the GMP Site 1 facility in Stony Brook, New York, which achieved commercial operation certification in January 2025.

Channel Component	Metric/Capacity/Value	Context/Timing
GMP Site 1 Capacity (Initial Modeling)	Approximately ten (10) grams per annum	For LineaDNA™ IVT template manufacturing
Projected Revenue Capacity (Site 1)	Ranging from $10 million to $30 million	Depending on product mix
Production Scale/Time	10mg to gram-scale production in 6-14 weeks	With multiple purification options
Supply Chain Sourcing Initiative	Completed long-term initiative to source critical input materials from U.S.-based suppliers	Announced April 21, 2025

Direct sales efforts target biopharmaceutical and diagnostics companies, evidenced by active negotiations for a GMP supply agreement with an mRNA therapeutic developer. A concrete example of a successful channel transaction is the seventh follow-on order from a global IVT manufacturer, valued at more than $600,000 for a multi-gram quantity of LineaDNA™.

Lead generation relies heavily on digital and scientific presence, which you can track through their corporate website and scientific outreach:

• Launched the LineaRx IVT Discovery Kit for rapid customer evaluation.
• Marketing LineaRNAP as a standalone product based on data confirming higher mRNA yields.
• Abstracts selected for poster presentations at upcoming mRNA and CAR T Industry Conferences.

The company's strategic realignment in June 2025 involved a 27% workforce reduction, projecting a 23% reduction in annual payroll costs, intended to concentrate resources behind LineaRx for scaling commercial adoption. The Therapeutic DNA Production Services Segment (LineaRx) saw revenues increase 44% Year-over-Year in the second quarter of fiscal 2025 ended March 31, 2025.

Direct supply and delivery are managed from the Stony Brook, New York, headquarters, which houses the GMP Site 1 facility. This facility is configured to deliver chemically modified LineaDNA IVT templates paired with the Company's proprietary RNA polymerase.

Applied DNA Sciences, Inc. (APDN) - Canvas Business Model: Customer Segments

You're looking at the customer base for Applied DNA Sciences, Inc. (now BNB Plus Corporation) as of late 2025, which is almost entirely centered on the LineaRx subsidiary following the June 27, 2025, cessation of Applied DNA Clinical Labs operations.

The primary focus is on supplying enzymatically produced synthetic DNA, positioning the LineaDNA and LineaIVT platforms as alternatives to conventional plasmid DNA (pDNA) methods for genetic medicine developers.

Here's a breakdown of the key customer groups being targeted by the LineaRx segment:

• Developers of mRNA therapeutics and vaccines: This group is a core target, evidenced by the receipt of follow-on orders for RUO-grade LineaDNA IVT templates from an APAC-based CDMO of mRNA vaccines and therapeutics.
• Gene therapy and adoptive cell therapy (CAR-T) companies: The Linea DNA platform achieved its first-in-human clinical validation in a CAR-T therapy under a Phase I clinical trial in the Czech Republic. The company is also presenting at upcoming CAR T Industry Conferences in August 2025.
• In Vitro Diagnostics (IVD) manufacturers requiring large-scale DNA: Applied DNA Sciences continued large-scale manufacturing and delivery of LineaDNA under supply agreements with these entities. A new follow-on LineaDNA order was announced in July 2025 from a global IVD manufacturer for use in a cancer diagnostic application.
• U.S.-based CRISPR and mRNA therapeutics developers: The company reported receiving a quantity of LineaDNA for use by a U.S.-based CRISPR and mRNA therapeutics developer.
• Global biopharma companies seeking pDNA alternatives: This segment is targeted by the platform's ability to produce high-fidelity DNA rapidly and scalably. The company previously gained evaluation customers including a multi-national biopharma company for the Linea™ IVT platform.

The financial context for this customer base in fiscal year 2025 shows the shift in focus:

Metric	Value (as of late 2025 reporting)	Reporting Period	Citation
Therapeutic DNA Production (LineaRx) Revenue Growth	44% increase	Year-over-year for Q2 Fiscal 2025 (ended March 31, 2025)
MDx Testing Services Revenue Change	33% decrease	Year-over-year for Q2 Fiscal 2025 (ended March 31, 2025)
GMP Site 1 Potential Annual Revenue	Between $10 million and $30 million	Based on initial projected manufacturing capacity
Cash and Cash Equivalents	$6.8 million	As of March 31, 2025
Cash and Cash Equivalents	Approximately $4.8 million	As of May 31, 2025
Private Placement Amount Announced	Up to $58 Million	October 2025
Forecasted Annual Revenue	$9MM	For period ending September 30, 2025

The company's strategic realignment involved a workforce reduction of approximately 27% of headcount, projecting a 23% reduction in annual payroll costs compared to the fiscal year ended September 30, 2024, to concentrate resources on LineaRx.

The LineaRx segment is designed to produce DNA in quantities from milligrams to grams.

Applied DNA Sciences, Inc. (APDN) - Canvas Business Model: Cost Structure

The cost structure for Applied DNA Sciences, Inc. is heavily weighted toward maintaining specialized operational capabilities and funding platform development, even following significant cost-cutting measures.

Operating losses remain a core component of the cost profile. For the third quarter of fiscal 2025, which ended June 30, 2025, Applied DNA Sciences reported an operating loss of $3.7 million. This follows an operating loss of $3.5 million in the second quarter of fiscal 2025 and $3.0 million in the first quarter of fiscal 2025. The monthly net cash burn from operations in Q3 fiscal 2025 was reported at $934 thousand.

High fixed costs are associated with operating the GMP manufacturing facility, Site 1, which was completed and certified for commercial operation in January 2025. This facility is central to the LineaRx strategy, with an initial projected annual revenue capacity estimated to range between $10 million and $30 million depending on the product mix.

Significant R&D expenditure is directed toward platform enhancement and new product development, specifically for the LineaDNA™ and LineaIVT™ technologies, as the company focuses exclusively on its synthetic DNA manufacturing business.

Salaries and benefits for specialized scientific and executive staff constitute a major ongoing operating expense, which the company has aggressively targeted for reduction through restructuring.

The company previously projected a 31% reduction in annual payroll expenses compared to the fiscal year ended September 30, 2024, as a result of restructuring initiated in December 2024. More recently, a restructuring authorized on September 30, 2025, which included a 60% workforce reduction, is projected to generate annualized cost savings of approximately $2.9 million.

Here's a quick look at recent financial performance metrics tied to costs:

Metric	Amount	Period
Operating Loss	$3.7 million	Q3 Fiscal 2025
Monthly Net Cash Burn (Operations)	$934 thousand	Q3 Fiscal 2025
Projected Annual Payroll Savings (Sept 2025 Restructuring)	$2.9 million	Annualized
Projected Annual Payroll Expense Reduction (Initial Restructuring)	31%	Compared to FY2024
One-Time Restructuring Charge (Sept 2025 Plan)	Approximately $1.4 million	Estimated Pre-Tax Charges

Key cost drivers and restructuring impacts include:

• High overhead related to maintaining the newly certified GMP Site 1 facility.
• Ongoing investment in LineaRx platform scaling and commercial adoption.
• A workforce reduction of approximately 27% in June 2025, which equated to a projected 23% reduction in annual payroll costs at that time.
• Cessation of operations at Applied DNA Clinical Labs, effective June 27, 2025, to reduce operating costs.
• One-time separation costs of approximately $300 thousand associated with the January 2025 workforce reduction.

Finance: draft 13-week cash view by Friday.

Applied DNA Sciences, Inc. (APDN) - Canvas Business Model: Revenue Streams

The current focus for Applied DNA Sciences, Inc. revenue generation is centered almost entirely on the LineaRx segment, following the exit from the DNA Tagging and Security Products and Services business segment in February 2025 and the cessation of operations at Applied DNA Clinical Labs (ADCL) in June 2025. The forecasted annual revenue for Applied DNA Sciences, Inc. for the fiscal year ending 2025-09-30 is set at $9 million.

To give you context on the year-to-date performance leading into that forecast, here is a look at the reported total revenues for the first three quarters of fiscal year 2025:

Fiscal Quarter End Date	Total Revenue Amount
December 31, 2024 (Q1 FY2025)	$1.2 million
March 31, 2025 (Q2 FY2025)	$983 thousand
June 30, 2025 (Q3 FY2025)	$304 thousand

Revenue from Therapeutic DNA Production Services (LineaRx segment) is the primary driver now that the company is exclusively focused on synthetic DNA manufacturing. For the second quarter of fiscal 2025, the LineaRx segment revenues showed a significant year-over-year increase of 44% compared to the same period in fiscal 2024. This increase in segment revenue was specifically attributed to two key factors:

• The timing of shipments for a second large-scale DNA manufacturing customer.
• A large shipment delivered to an existing large-scale DNA manufacturing customer.

Sales of LineaDNA™ IVT templates and finished DNA constructs are directly supported by the newly certified GMP Site 1 facility in Stony Brook, New York, which achieved commercial operation certification in January 2025. This facility enables the enzymatic manufacture of Linea DNA™ IVT templates, which are critical for producing mRNA clinical trial materials. The initial projected manufacturing capacity of Site 1 is approximately ten grams per annum, which supports potential annual revenues in the range of $10 million to $30 million, depending on the product mix.

Follow-on orders from existing large-scale DNA manufacturing customers are a confirmed source of revenue within the LineaRx segment. During the second quarter of fiscal 2025, Applied DNA Sciences, Inc. reported receiving specific follow-on orders, which included:

• A quantity of RUO-grade LineaDNA IVT templates to an APAC-based CDMO of mRNA vaccines and therapeutics.
• A quantity of LineaDNA to a U.S.-based CRISPR and mRNA therapeutics developer.
• Continued large-scale manufacturing and delivery of LineaDNA under existing supply agreements with global manufacturers of in vitro diagnostics (IVDs).

Licensing and royalty fees from proprietary LineaRNAP™ technology represent a developing revenue stream. Applied DNA Sciences, Inc. launched industry marketing for LineaRNAP as a standalone product in the third quarter of fiscal 2025, based on data confirming its use in conventional mRNA production workflows to achieve higher mRNA yields and integrity. The company also continues to market LineaRNAP as a component of its integrated LineaIVT solution.